Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Are you currently challenged by unpredictable off-target toxicity, limited efficacy in solid tumors, and difficulties in controlling T cell activity in your development progress? Creative Biolabs' Solid Tumor Targeting CAR-T Development Services with Adapter Switch overcome these hurdles by integrating proprietary universal CAR architectures with chemically or protein-based adapter systems. This design enables dose-dependent and tunable control over T cell activation, significantly improving safety profiles while maintaining anti-tumor potency.
The Adapter Switch is a precision targeting technology that utilizes bifunctional adapter molecules to dynamically bridge universal CAR-T cells with tumor antigens. In CAR-T therapy, this platform enables redirection of a single universal CAR-T product against multiple tumor antigens simply by exchanging different adapters, thereby effectively addressing tumor heterogeneity and antigen escape in solid tumors. This strategy not only significantly enhances the safety, controllability, and applicability of CAR-T therapy, but also represents a revolutionary platform to overcome key challenges in the solid tumor microenvironment.
Fig.1 Key elements of adapter-switch CAR-T platforms.
Creative Biolabs' Solid Tumor Targeting CAR-T Development Services with Adapter Switch deliver tailored, programmable cell therapy solutions designed to overcome the critical limitations of conventional CAR-T systems. We provide a single, universal T-cell platform that can be dynamically directed to target multiple antigens, or even conditionally deactivated, using co-administered small molecule or protein adapters. Our strategy enables superior safety management through dose-dependent control and unlocks efficacy potential in previously intractable solid tumors and heterogeneous cancers.
Creative Biolabs offers adaptable platforms tailored to specific requirements, primarily focused on solving the challenge of solid tumors and maximizing therapeutic control.
This system employs a universal FITC-specific CAR and a bispecific adapter. The adapter specifically bridges and activates T cells only upon mediating their binding to solid tumors overexpressing folate receptors. This design enables precise, dose-dependent control of T cell activity and facilitates flexible retargeting by simply exchanging the tumor-targeting module.
The SUPRA CAR system utilizes a split CAR design and protein-based adapters. By adjusting the combination and concentration of different adapters, it can execute complex recognition patterns based on Boolean logic operations using multiple antigens. This allows for highly precise targeting of tumor cell populations defined by specific surface marker combinations.
Required Starting Materials:
Key steps:
Final Deliverables:
How does the Adapter Switch system improve safety compared to traditional CAR-T?
Traditional CAR-T is permanently "ON." Our system is acutely dependent on the co-administered adapter molecule. By controlling the adapter's concentration (dosing), you can precisely titrate T cell activity in real-time or rapidly clear the adapter to halt T cell function entirely, effectively serving as a fine-tuned safety valve against toxicity.
Can this platform be used to target multiple antigens simultaneously, such as for heterogeneous tumors?
Absolutely, this is a core feature. We can design and co-administer multiple adapter molecules, each targeting a different tumor antigen. Our universal T cell platform will respond to all of them, providing a powerful strategy to overcome tumor escape mechanisms and heterogeneity.
Creative Biolabs provides leading solid tumor CAR-T development services centered on proprietary adapter switch platforms. Our solutions deliver precise, dose-titratable activity control and multi-antigen Boolean logic targeting to enhance safety against complex tumor heterogeneity. With a universal CAR backbone adaptable to various targets, we accelerate therapeutic development while ensuring optimized persistence and penetration within the solid tumor microenvironment.
"Using Creative Biolabs' CAR-T Development with Adapter Switch in our research has significantly improved the precision of our dose-titration studies. We can now confidently fine-tune cytotoxicity in pre-clinical models, which was impossible with rigid, traditional CARs." Dr. J**es S.
"The ability to switch targets and address tumor heterogeneity is a game-changer. We utilized their LILRB4-based universal CAR with success; it dramatically facilitated our efforts to target previously untreatable solid tumor indications by overcoming immunosuppression pathways." P**aul A.
We invite you to discuss how our modular, adapter-controlled technology can accelerate your pipeline and enhance the safety and efficacy of CAR-T therapy.
Initiate a collaboration with our experts to address your specific project challenges.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
